Background {#Sec1}
==========

Coronavirus infection is a novel, highly contagious respiratory disease caused by SARS-CoV-2 affecting people across the world \[[@CR1]\]. The most frequent symptoms are fever, dyspnea, cough, or myalgia \[[@CR2]\]. Although various signs and symptoms have been reported for this disease, some of them are not clear yet. It may involve both the central nervous system (CNS) and peripheral nervous system (PNS). In this regard, headache, vertigo, cognitive impairment, epilepsy, acute cerebrovascular event ataxia, ageusia, anosmia, neuralgia, and Guillain-Barre syndrome are some of the reported neurological manifestations \[[@CR3]--[@CR5]\].

According to previous reports, viral infections including COVID-19 may play a role as a potential risk factor in developing cerebrovascular diseases such as acute ischemic stroke especially in patients with the severe form of infection \[[@CR6]\].

The role of COVID-19 in initiating proinflammatory and hypercoagulable state has been well described \[[@CR7]\]. Also, because of inflammation, hypoxia, immobilization, and diffuse intravascular coagulation (DIC), patients with COVID-19 are at a higher risk of both venous and arterial thromboembolic events. Recently, heparin has been associated with lower mortality in severe cases of COVID-19 or with elevated D-dimer \[[@CR8]\]. However, the mechanism and its pathology are rarely understood.

There are currently limited data about patient's characteristics, extent of lung involvement, and other factors in the patients with stroke and COVID-19. This series is presented to point out to physicians to keep cerebrovascular attacks in mind as an important condition in patients with COVID-19 that may need urgent interventions. In addition, the other aim of this study was to show coronavirus as a causative agent for stroke which is unrelated to age and lung involvement extension.

Cases {#Sec2}
-----

Our cases were patients presented to our academic tertiary hospital, stroke unit, with clinical symptoms of stroke from March 2020 to the end of April 2020. We exclude patients older than 55 and all others who had evidence of cardiac arrhythmia or cardiac valvular disease based on electrocardiogram, transthoracic and transesophageal echocardiography, and 24-h Holter monitoring findings. Although all patients primarily presented with neurological symptoms, the diagnosis of COVID-19 was made based on positive nasopharyngeal polymerase chain reaction (PCR) and lung CT scan except one of them who was a 49-year-old female with previous diagnosis of COVID-19 who was discharged from another hospital and admitted to our stroke unit 5 days later.

The mean age (±standard deviation \[SD\]) was 43.5 ± 7.42 (range 33--53 years) and half of them were male. COVID-19 symptoms were evaluated by history taking except one of our cases (33 years old female) who presented altered levels of consciousness and fever. The most common sign and symptom of COVID-19 were fever (four/six), myalgia (four/six), cough (three/six), and dyspnea (three/six). All patients had O~2~ saturation below 92% in room air while none of them were hypotensive. Half of the patients had history of hypertension and one case had diabetes mellitus.

Mean (±standard deviation) of National Institutes of Health Stroke Scale (NIHSS) for the patient was 10.16 ± 7.13 (ranged 5--24). Detailed clinical features and outcomes of the patients are noted in Table [1](#Tab1){ref-type="table"}. In addition, the initial laboratory findings are shown in Table [2](#Tab2){ref-type="table"}.Table 1Demographic, clinical features, and outcome of the patientsPatient No.Age, year/genderComorbiditiesFeverCOVID-19 symptomsStroke symptomsO~2~ sat on room air (%)NIHSSHospital length of stayOutcome133/F−+lethargyReduced level of consciousness, global aphasia, right side hemiplegia85245Death239/M−+Cough, headache, myalgia, dyspneaLeft side hemiparesis, homonymous hemianopia, sensory deficit, dysarthria89910Discharged349/FHTN−MyalgiaLeft side hemiplagia,heminimous hemianopia, dysarthera901114Discharged440/M−−Myalgia, dyspneaRight side hemiparesis, dysarthera8967Discharged553/MHTN+Cough, diarrheaLeft side hemiparesis, dysarthria9157Discharged647/ FDM/HTN+Myalgia, cough and dyspneaRight side hemiparesis, dysarthria8269Discharged*F* female, *M* male, *HTN* hypertension, *NIHHS* National Institutes of Health Stroke ScaleTable 2Summary of baseline laboratory findings123456Summery (mean ± SD)White blood cell count8000550087007400450090007183.33 ± 1808.22Neutrophil count5600470069606364292576505699.83 ± 1705.38Lymphocyte count24008001392888157513501400.83 ± 575.38Hemoglobin (mg/dL)9.810.711.816.815.812.512.89 ± 2.80Platelet × 10^3^305183146223101210194.66 ± 69.98CRP (mg/L)2412275121015.0 ± 8.57LDH (μ/L)3453471393356430460555.16 ± 413.24Cr (mg/dL)0.80.81.091.21.21.041.02 ± 0.18AST (μ/L)16149421171128.83 ± 32.09ALT (μ/L)151110613101428.16 ± 38.17ALP (μ/L)143134415209204162211.16 ± 104.52Albumin (g/dL)5.014.83.94.84.14.34.48 ± 0.44D-Dimer7288109546826001293844.50 ± 250.63PT (s)13131314131413.33 ± 0.51PTT (s)28403040383034.33 ± 5.57INR1111.111.11.03 ± 0.51*CRP* C-reactive protein, *LDH* lactic acid dehydrogenase, *Cr* creatinine, *BUN* blood urea nitrogen, *AST* aspartate transaminase, *ALT* alanine transaminase, *ALP* alkaline phosphatase, *PT* prothrombin time, *PTT* partial thromboplastin time, *INR* international normalized ratio

All patients underwent imaging studies for stroke and also chest CT scan with low-dose protocol \[[@CR9]\]. The initial chest CT scan evaluated for estimation of lung involvement score using zonal involvement percentage method with the maximum score of 24 \[[@CR10]\]. The mean score (±SD) was 13.16 ± 6.49 (ranged 2--16) and bilateral ground glass opacities were the most predominant pattern (Fig. [2](#Fig2){ref-type="fig"}).

Brain CT scan findings revealed the stroke territories as follows: right middle cerebral artery (MCA) infarction (*n* = 3), left MCA (*n* = 2), and left basal ganglia infarction (*n* = 1), and the majority of the patients had large vessel stroke. Figures [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}, and [3](#Fig3){ref-type="fig"} show brain CT beside lung CT scans of three patients. Our data demonstrated that the majority of our patients had low lung involvement rate while they had more severe conditions based on NIHSS score. Carotid duplex was negative for any significant findings (stenosis, atherosclerotic plaque, or dissection) and results of transcranial color-coded duplex ultrasonography (TCCS) have been summarized in Table [3](#Tab3){ref-type="table"}.Fig. 1Thirty-three-year-old female with fever and reduced level of consciuosness who had a history of exposure to known case of COVID-19 in his family. **a** Left MCA territory hypodencities in brain CT scan (**a**) and increased signal of cortex, white matter, head of left caudete, lentiform nulclei, and anterior horn of internal capsule in T2 and FLAIR brain MRI sequences (**c**, **d**), in favor of subacute infarct. **b** Small subpleuroal consodiation in superior segment of right lung inferior lobe highly suggestive for COVID-19Fig. 2Thirty-nine-year-old male with fever, cough, and mylgia from 6 days before presentation and sudden onset of left side hemiplegia and dysartheria. **a** Hypodensities in right MCA branch territorty suggestive of subacute infarct. **b** Diffused ground glass opacities with interalobular septal thickening in superior segment of left lung lower lobes highly suggestive for COVID-19Fig. 3Forty-nine-year-old female with pervious history of moderate COVID-19 who admitted to our stroke unit with left side hemiplegia, sensory deficiet, and dysarthria. **a** Wedge-shaped hypodensities in right MCA territory consistent with subacute infarct in brain CT scan. **b** Diffused peripheral and central consoliadtion patches with crazy paving pattern in some areas consistent with late phase of COVID-19Table 3Summary of baseline imaging findingsPatient No.Infarcted area based on imagingLung CT scan findings (lung involvement score out of 24)TCCS1Left middle cerebral artery territorySmall subpleuroal consodiation in right lower lobes (2)Flow was not detected in Left MCA.2Right middle cerebral artery territoryGround glass opacities in left lower lobes (3)Poor temporal window3Right middle cerebral artery territoryDiffused consoliadtion patches (16)Normal4Left middle cerebral artery territoryBilateral peripheral ground glass opacities in lower zones (4)Normal5Right middle cerebral artery territoryBilateral peripheral ground glass opacities in middle zones (8)Normal6Left basal gangliaRight side lower and middle zones ground glass with sub pleural ground glass opacities in left lower zone (10)Poor temporal window*TCCS* transcranial color-coded duplex ultrasonography, *MCA* middle cerebral artery

Regarding our national guidelines, all patients were placed on hydroxychloroquine 400 mg stat and lopinavir/ritonavir 400/100 mg twice daily and intravenous antibiotic. In addition, because all the patients were presented to the emergency room 3 h after their symptom initiation, they were not candidate for thrombolytic therapy so all of them underwent medical treatment with ASA and Plavix for secondary prevention. All patients were followed up to the study endpoint, five patients were discharged; however, one case did not survive.

Discussion {#Sec3}
==========

This series showed the co-occurrence of stroke and COVID-19 in adults younger than 55 years of age. To date, there is limited data on the association of COVID-19 and ischemic stroke mechanism, clinical course, prevention, management, and risk stratification.

Valderrama et al. reported a 52-year-old man with COVID-19 who presented with sudden onset hemiparesis and aphasia (NIHSS: 20) on his seventh day of treatment and brain CT scan confirmed the diagnosis of stroke in MCA territory. On further work up, they did not find any risk factor for stroke \[[@CR11]\].

In this study, the majority of our patients (five/six) were not known cases of COVID-19 infection and all of them were admitted to our stroke unit with neurological complaints while Mao et al. reported the occurrence of stroke in approximately 2% of COVID-19 patients during their admission \[[@CR12]\]. In a study by TJ Oxley et al., large-vessel strokes were presented in five COVID-19 cases younger than 50 years old, and unlike our patients, all of them had severe COVID-19 \[[@CR13]\].

Avula et al., described acute stroke in four old-aged patients (range 73--88 years) with confirmed diagnosis of COVID-19, while the oldest patient in this study was 53 years old \[[@CR14]\].

It seems that factors such as direct virus invasion, inflammatory processes, cytokine release, hypoxemia, hypotension, or vasculitis are possible mechanisms of coronavirus affecting the nervous system.

This is the first study evaluating the association of long involvement extension and stroke severity. In this regard, our cases showed that lung involvement extension may be unrelated to developing a stroke and its severity based on NIHSS. On the other hand, D-Dimer level may play a critical role as a prognostic factor as elevated D-Dimer levels were seen in all of our patients.

Poggiali et al. reported two cases of COVID-19 who complicated with DVT and PE after at least 10 days since their symptoms started \[[@CR15]\]. Also, based on a recent study, COVID-19 could be predisposed to venous and arterial thromboembolism leading to diffuse intravascular coagulation, severe inflammation, immobilization, and hypoxia \[[@CR16]\].

An investigation on ICU-admitted patients with COVID-19 showed that the incidence of thrombotic complications was extremely high (31%). The study revealed that pharmacological thrombosis prophylaxis is critically important to be added to the treatment regimen of all COVID-19 patients admitted to ICU \[[@CR16]\].

Conclusion {#Sec4}
==========

In conclusion, COVID-19 can cause thrombotic complications, hyper-inflammation, and tissue damage, which may increase the risk of ischemic stroke in young and middle aged patients even in early stages and mild forms of COVID-19.

**Publisher's note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The authors declare that they have no conflict of interest.

The study protocol was approved by the ethics committee of the Shahid Beheshti University of Medical Sciences (IR.SBMU.RETECH.REC.1399.115).

Written informed consents were obtained from patients or their guardian.
